U.S. Department of Health and Human Services
Paul Kovac

 Contact Info

Tel: 301-496-3569
Email: kovac@mail.nih.gov

 Select Experience

  • Senior InvestigatorLaboratory of Bioorganic Chemistry, NIDDK, NIH1983-present
  • Group LeaderBachem, Inc.1981-1982
  • Senior ScientistInstitute of Chemistry, Slovak Academy of Sciences1969-1981
  • Post-docPurdue University, Department of Biochemistry1967-1968
  • Ph.D.Institute of Chemistry, Slovak Academy of Sciences1967
  • M.S.Slovak Technical University1962

 Related Links


Paul Kovac, Ph.D.

Section Chief, Carbohydrates SectionLaboratory of Bioorganic Chemistry
  • Chemistry/Chemical Biology

Research in Plain Language

The primary focus of the Carbohydrates Section in the NIDDK’s Bioorganic Chemistry Laboratory is to develop safer, highly effective vaccines. Instead of using actual disease-causing organisms that have been killed in vaccine development, we use components that are synthesized especially for this purpose. Vaccines made from killed or weakened disease organismscan often cause high fevers (they are pyrogenic) or have other undesirable side effects.

Sometimes the outer coat of an actual disease-causing organism is not the optimal antigen (a substance that causes your immune system to produce antibodies against it) for a strong immune response. In order to enhance this response, the carbohydrate portion of this coatingcan be combinedor conjugated with asuitable carrier, often after removal of the toxic Lipid A (the toxic part). The resulting material is called aneoglycoconjugate.

Our preferred approach is to create a synthetic carbohydrate molecule—a synthetic oligosaccharide—that is chemically similar to the carbohydrate coat of the actual disease-causing organism and evokes a strong immune response when it is conjugated with a carrier. The resulting construct does not have pyrogenic or other undesirable side effects. Our current objective is to develop safe conjugate vaccines for two deadly diseases, cholera and anthrax, using such synthetic components.

There are many ways that synthetic oligosaccharides that mimic the carbohydrate bacterial coat could be made and linked to a carrier. Therefore, part of our work is to study how various factors, such as the size of the carbohydrate fragment and mode of linking,affect the ability of the conjugated vaccine to evoke a strong protective immune response ina vaccinated person. For many years, we have used a systematic, staged approach to develop synthetic oligosaccharides and the conjugate vaccines made with them. This approach starts with synthesizing fragments of the weakly antigenic carbohydrate coat of the disease organism, finding the fragments that evoke the strongest production of effective antibodies, and conjugating these fragments to suitable carriers. We then test how well this conjugated compound works as a protective vaccine.